Journal of Neurology

, Volume 255, Issue 10, pp 1473–1478 | Cite as

Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS

  • D. L. Arnold
  • D. Campagnolo
  • H. Panitch
  • A. Bar-Or
  • J. Dunn
  • M. S. Freedman
  • S. K. Gazda
  • T. Vollmer
ORIGINAL COMMUNICATION

Abstract

Background

Glatiramer acetate (GA) therapy following brief, low-dose induction with mitoxantrone was safe and more effective than GA alone in suppressing inflammatory disease activity, as determined by a significant reduction in gadolinium (Gd)- enhancing MRI lesions, in a 15- month, randomized, single-blind study of relapsing-remitting multiple sclerosis (RRMS) patients.

Objective

To determine whether effects on MRI markers of disease burden and tissue damage support and extend data on the benefits of mitoxantrone induction therapy before initiation of long-term GA therapy.

Design/methods

40 RRMS patients, aged 18 to 55 years, with 1–15 Gd-enhancing lesions on screening MRI and EDSS score 0–6.5 were randomized to receive GA (20 mg/d SC), starting 2 weeks after the last of 3 monthly mitoxantrone infusions (36 mg/m2 total; n = 21), or to GA alone (20 mg/d SC; n = 19), for a total of 15 months. MRIs were obtained at baseline and months 6, 9, 12, and 15.

Results

At baseline, mean (± SD) age was 37.2 ± 9.7 years; disease duration, 3.5 ± 4.8 years; EDSS score, 2.3 ± 1.1; and number of Gd-enhancing lesions, 3.75 ± 3.95. Reductions in Gd-enhancing lesions (RR = 0.30, 95 % CI, 0.11–0.86, p = 0.0147) and relapse activity favoring mitoxantrone- GA were accompanied by significant differences in changes in T2w lesion volume (p = 0.0139), T1w hypointense lesion volume (p = 0.0303), and proportion of Gdenhancing lesions that evolved into black holes (p = 0.0023) compared with GA alone.

Conclusions

Longterm continuous GA after brief, low-dose mitoxantrone induction is safe and more effective than GA alone. A trend toward decreased clinical disease activity was accompanied by major effects on MRI measures of disease burden and severe tissue injury.

Key words

glatiramer acetate mitoxantrone combination MRI multiple sclerosis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Aharoni R, Eilam R, Domev H, Labunskay G, Sela M, Arnon R (2005) The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice. Proc Natl Acad Sci 102:19045–19050PubMedCrossRefGoogle Scholar
  2. 2.
    Bitsch A, Kuhlmann T, Stadelmann C, Lassmann H, Lucchinetti C, Bruck W (2001) A longitudinal MRI study of histopathologically defined hypointense multiple sclerosis lesions. Ann Neurol 49:793–796PubMedCrossRefGoogle Scholar
  3. 3.
    Chen M, Gran B, Costello K, Johnson K, Martin R, Dhib-Jalbut S (2001) Glatiramer acetate induces a Th2- biased response and crossreactivity with myelin basic protein in patients with MS. Mult Scler 7:209–219PubMedGoogle Scholar
  4. 4.
    Chen M, Valenzuela RM, Dhib-Jalbut S (2003) Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor. J Neurol Sci 215:37–44PubMedCrossRefGoogle Scholar
  5. 5.
    Comi G, Filippi M, Wolinsky JS, The European/Canadian Glatiramer Acetate Study Group (2001) European/ Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 49:290–297PubMedCrossRefGoogle Scholar
  6. 6.
    Copaxone® (glatiramer acetate injection) prescribing information. Kfar- Saba, Israel: Teva Pharmaceutical Industries Ltd.; 2006Google Scholar
  7. 7.
    Dhib-Jalbut S (2002) Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology 58:S3–S9PubMedCrossRefGoogle Scholar
  8. 8.
    Dhib-Jalbut S, Chen M, Said A, Zhan M, Johnson KP, Martin R (2003) Glatiramer acetate-reactive peripheral blood mononuclear cells respond to multiple myelin antigens with a Th2- biased phenotype. J Neuroimmunol 140:163–171PubMedCrossRefGoogle Scholar
  9. 9.
    Filippi M, Rovaris M, Rocca MA, Sormani MP, Wolinsky JS, Comi G, et al. (2001) Glatiramer acetate reduces the proportion of new MS lesions evolving into “black holes.” Neurology 57:731–733PubMedGoogle Scholar
  10. 10.
    Fox EJ (2004) Mechanism of action of mitoxantrone. Neurology 63(Suppl 6):S15–S18PubMedGoogle Scholar
  11. 11.
    Gran B, Tranquill LR, Chen M, Bielekova B, Zhou W, Dhib-Jalbut S, et al. (2000) Mechanisms of immunomodulation by glatiramer acetate. Neurology 55:1704–1714PubMedGoogle Scholar
  12. 12.
    Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing remitting multiple sclerosis: Results of a phase III multicenter, doubleblind, placebo-controlled trial. Neurology 45:1268–1276PubMedGoogle Scholar
  13. 13.
    McDonald WI, Compston A, Edan G, Goodkin D, Hartung H-P, Lublin FD, et al. (2001) Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 50:121–127PubMedCrossRefGoogle Scholar
  14. 14.
    Novantrone® (mitoxantrone) prescribing information. Seattle, Washington: Immunex Corporation; 2002Google Scholar
  15. 15.
    Ramtahal J, Jacob A, Das K, Boggild M (2006) Sequential maintenance treatment with glatiramer acetate is safe and can limit exposure to immunosuppression in very active relapsing remitting multiple sclerosis. J Neurol 253:1160–1164PubMedCrossRefGoogle Scholar
  16. 16.
    Smith SM, De Stefano N, Jenkinson M, Matthews PM (2001) Normalized accurate measurement of longitudinal brain change. J Comp Assist Tomog 25:466–475CrossRefGoogle Scholar
  17. 17.
    Smith SM, Zhang Y, Jenkinson M, Chen J, Matthews PM, Federico A, et al. (2002) Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimag 17:479–489CrossRefGoogle Scholar
  18. 18.
    Sormani MP, Rovaris M, Valsasina P, Wolinsky JS, Comi G, Filippi M (2004) Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis. Neurology 62:1432–1434PubMedGoogle Scholar
  19. 19.
    Vollmer T, Panitch H, Bar-Or A, Dunn J, Freedman MS, Gazda SK, et al. (2008) Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. Mult Scler 14(5):663–670PubMedCrossRefGoogle Scholar
  20. 20.
    Wolinsky JS (2004) Glatiramer acetate for the treatment of multiple sclerosis. Exp Opin Pharmacother 5:875–891CrossRefGoogle Scholar

Copyright information

© Springer 2008

Authors and Affiliations

  • D. L. Arnold
    • 1
  • D. Campagnolo
    • 2
  • H. Panitch
    • 3
  • A. Bar-Or
    • 1
  • J. Dunn
    • 4
  • M. S. Freedman
    • 5
  • S. K. Gazda
    • 6
  • T. Vollmer
    • 2
  1. 1.NeuroRx ResearchMontrealQuebec Canada
  2. 2.PhoenixUSA
  3. 3.BurlingtonUSA
  4. 4.KirklandUSA
  5. 5.OttawaCA
  6. 6.San AntonioUSA

Personalised recommendations